Loading live market data…

Novartis AG

NYSE:NVS

$150.36 USD

-$3.01 (-1.96%)

Volume
1.24M
Average Volume
1.74M
Market Capitalization
$286.9B
P/E Ratio
21.68
Dividend Yield
3.02%
Price Target
$170.00
Year High
$170.46
Year Low
$112.34
Day High
—
Day Low
—
Payout Ratio
$0.61
Current Ratio
$0.85

Industry, Sector & symbol

Stock Exchange NYSE
CEO Vas Narasimhan
Industry Drug Manufacturers - General
Sector Healthcare
Current Symbol NVS
CUSIP 66987V109
CIK 0001114448
Web https://www.novartis.com
Phone 41 61 324 1111
Currency USD
Employees 75267
Country CH

Liquidity

Debt-to-Equity Ratio 1.22
Payout Ratio 0.61
Current Ratio 0.85
Quick Ratio 0.65
Cash Ratio 0.22

Sales & Book Value

Annual Sales $54.81B
Price / Sales 5.21
Cash Flow 8.71
Price / Cash Flow 17.37
Price / Book 7.48

Price Target and Rating

Average Stock Price Forecast $170.00
High Stock Price Forecast $170.00
Low Stock Price Forecast $170.00
Forecast Upside/Downside -11.55%
Consensus Rating Neutral
Rating Score(0-5) 3
Research Coverage 25 Analysts

Profitability

EPS (Most Recent Fiscal Year) $7.19
Trailing P/E Ratio 21.68
PEG Ratio 2.53
P/E Growth 2.53
Net Income $14.06B
Net Margin 24.31%
Pretax Margin 28.35%
Return on Equity 31.54%
Return on Assets 11.34%

Financials Score

AltmanZ Score 3.53
Piotroski Score 6.00
Working Capital -4.77B
Total Assets 118.53B
Ebit 17B
Market Cap 290.34B
Total Liabilities 79.6B

Poll Results

About Novartis AG (NYSE:NVS) Stock

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland. ...

How To Build A $50,000 Dividend Portfolio In Today's Market

2026-07-13 13:45:49

The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize a diversified mix of ETFs and individual stocks across sectors, balancing dividend income, growth, and capital appreciation while mitigating downside risk. Key metrics include a 3.75% weighted average dividend yield, low payout ratios, and low beta factors, supporting long-term portfolio resilience.

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

2026-07-09 12:12:04

Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growth innovative assets.

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

2026-07-09 08:15:04

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger

2026-07-08 12:36:02

Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.

Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon

2026-07-07 08:40:52

Novartis continues to favor in-licensing and bolt-on acquisitions. The Myricx Bio acquisition expands Novartis' ADC pipeline with novel NMTi payloads, but commercial impact is several years away. Avidity's del-brax and Ionis's pelacarsen, both late-stage assets, offer multibillion-dollar peak sales potential with pivotal data expected in the second half of the year.

Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition

2026-07-06 15:41:05

NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.

Novartis to Buy Myricx Bio for Up to $1.5 Billion

2026-07-06 01:52:00

The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis's oncology capabilities.

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

2026-07-06 01:26:17

Swiss drugmaker Novartis said on Monday it had ​agreed to pay up to $1.5 ‌billion for U.K.-based biotechnology firm Myricx Bio in a deal expected ​to close in the second ​half of 2026.

Frequently Asked Questions

What is the current Novartis AG (NVS) stock price?

Novartis AG(NYSE:NVS) stock price is $150.36 in the last trading session. During the trading session, NVS stock reached the peak price of $170.46 while $112.34 was the lowest point it dropped to. The percentage change in NVS stock occurred in the recent session was --1.96% while the dollar amount for the price change in NVS stock was -$-3.01.

NVS's industry and sector of operation?

The NYSE listed NVS is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of NVS?

Sloan Simpson | Global Head of Investor Relations
Karen L. Hale | Chief Legal & Compliance Officer
Paul Penepent | Head of Group Financial Reporting and Accounting
Steffen Lang | President of Operations
Vasant Narasimhan | Chief Executive Officer

How many employees does NVS have?

Number of NVS employees currently stands at 75267. NVS operates from Lichtstrasse 35, Basel, BS 4056, CH.

Link for NVS official website?

Official Website of NVS is: https://www.novartis.com

How do I contact NVS?

NVS could be contacted at phone #41 61 324 1111 and can also be accessed through its website. NVS operates from Lichtstrasse 35, Basel, BS 4056, CH.

How many shares of NVS are traded daily?

The average number of NVS shares traded daily for last 3 months was 1.74M.

What is the market cap of NVS currently?

The market value of NVS currently stands at $286.9B with its latest stock price at $150.36